On Wednesday, Shares of Medtronic PLC (NYSE:MDT), gained 1.28% to $77.56.
Medtronic plc, declared that its Micra Transcatheter Pacing System (TPS) and Hybrid Closed Loop system have both earned the 2015 `Best of What`s New` award in the health category by Popular Science, the world`s largest science and technology magazine.
Selected after careful evaluation of thousands of submissions, the Micra TPS and Hybrid Closed Loop system, which comprises an insulin pump and a continuous glucose monitor sensor, are among the 100 honorees that represent a noteworthy leap forward in their respective categories. All winners will be featured in the magazine`s December issue, available now.
At less than one-tenth the size of traditional pacemakers, the Micra TPS is the world`s smallest pacemaker yet provides the most advanced pacing technology available for patients. It is cosmetically invisible and small enough to be delivered with minimally invasive techniques through a catheter, and implanted directly into the heart. Comparable in size to a large vitamin, the Micra TPS does not require the use of wires, known as “leads,” to deliver pacing therapy; rather, its flexible tines attach to the interior of the right ventricle. In the United States, the Micra TPS is an investigational device and not yet approved for commercial use. The device was awarded CE Mark (Conformité Européenne) in April 2015, with approval for 1.5T and 3T full body MRI scanning providing patients with access to the most advanced imaging diagnostic procedures.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
Shares of Marvell Technology Group Ltd. (NASDAQ:MRVL), declined -0.24% to $8.48, during its last trading session.
Marvell Technology Group Ltd., declared that on November 12, 2015 it had presented a compliance plan to The NASDAQ Stock Market (“NASDAQ”) to support its request for an extension of time to March 8, 2016 to regain compliance with continued listing requirements. Following NASDAQ rules, Marvell’s securities will remain listed on the NASDAQ Global Select Market pending NASDAQ’s review of the plan of compliance plan. Marvell intends to take all necessary steps to achieve compliance with the NASDAQ continued listing requirements as soon as practicable.
Marvell also declared that it presently anticipates issuing preliminary financial information for the third fiscal quarter ended October 31, 2015 by early December 2015.
Marvell Technology Group Ltd. designs, develops, and markets analog, mixed-signal, digital signal processing, and embedded and standalone integrated circuits. It offers mobile and wireless products comprising communications and applications processors; thin modems; and connectivity solutions, counting Wi-Fi, Bluetooth, near field communication, and FM; and mobile computing products, in addition to silicon solutions and Kinoma software.
Finally, Shares of AbbVie Inc (NYSE:ABBV), ended its last trade with 1.01% gain, and closed at $60.99.
AbbVie, declared data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100 percent in genotype 1 (GT1), 96-100 percent in genotype 2 (GT2) and 83-94 percent in genotype 3 (GT3) patients.1,2,3 These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Separately, in a late-breaking presentation of the SURVEYOR-I study, data show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR12 rate of 97 percent
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.